SHH and ameloblastoma: Keratocystic odontogenic tumour, which is in the same odontogenic tumor group as ameloblastoma, and also has PTCH dysfunction implicated in its pathogenesis has been shown to respond significantly to cyclopamine in a dose-dependent manner by targeting the SHH pathway [18].